Fact Sheet
Improving the science of abuse assessment before a drug is marketed is a unified goal for the FDA and pharmaceutical industry. It is the hope that…
Page
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.
Poster
Extended-release (ER) opioid formulations are often targeted for misuse and abuse because they contain high amounts of opioid. An oral…
Poster
Abuse deterrent formulations of opioid medications (ADOs) may help curtail the widespread abuse, misuse, and diversion of these products.With the…
Poster
Abuse of prescription opioids continues to be a serious public health concern, with as many as 12.5 million individuals aged 12 or older reporting…
Resource
14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation,…
Poster
Hydrocodone bitartrate (HB) and acetaminophen (APAP) combination products are known to be abused via oral, intranasal, and intravenous…
Poster
Onboarding is the process of welcoming new employees into an organization and providing them with the tools, resources, and knowledge to become…
Poster
Human abuse potential (HAP) studies are conducted to determine the potential abuse of a drug that has rewarding properties. Abuse potential refers to…
Capability
PRA’s dedicated early phase professionals leverage proven expertise in renal and hepatic impairment to provide clients with high quality ECG…